SCHEMBL4581404

SCHEMBL4581404

NNc1nc2c(N)ncnc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 8/20 0.41
PI4K2B Q8TCG2 8/20 0.41
PI4K2A Q9BTU6 8/20 0.41
PI4KB Q9UBF8 8/20 0.41
ADORA2A P29274 2/20 0.40
ADORA1 P30542 2/20 0.40
ERAP1 Q9NZ08 1/20 0.39
NUDT1 P36639 2/20 0.37
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
XDH P47989 2/20 0.35
LRRK2 Q5S007 2/20 0.35
RET P07949 1/20 0.35
LMNA P02545 1/20 0.35
DRD3 P35462 1/20 0.35
PIK3CG P48736 2/20 0.35
ADORA2B P29275 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42313 0.78 ADORA2A (0.42) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL42336 0.75 PIK3CG (0.42) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL159639 0.75 ADORA2A (0.40) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL842439 0.75 ADORA2A (0.40) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL12620888 0.75 ADORA2A (0.40) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL8565 0.75 ADORA2A (0.58) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL160304 0.75 ADORA2A (0.40) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL953009 0.75 NUDT1 (0.41) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL842890 0.75 ADORA2A (0.40) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL843216 0.75 ADORA2A (0.40) PI4KAPI4K2BPI4K2API4KBADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070933-A1 Purine, Pyrimidine, and Azaindole Derivatives SERENEX, INC. 2008-03-20 US claimed
WO-2008024981-A1 PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS SERENEX, INC. (US) 2008-02-28 WO claimed
US-20080070933-A1 Purine, Pyrimidine, and Azaindole Derivatives SERENEX, INC. 2008-03-20 US disclosed
US-20080070933-A1 Purine, Pyrimidine, and Azaindole Derivatives SERENEX, INC. 2008-03-20 US disclosed
US-20080070933-A1 Purine, Pyrimidine, and Azaindole Derivatives SERENEX, INC. 2008-03-20 US disclosed
WO-2008024981-A1 PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS SERENEX, INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070933-A1 Purine, Pyrimidine, and Azaindole Derivatives P2RX7, P2RX5, P2RX3 PI4KA 2993/4885PI4K2B 3024/4885PI4K2A 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.